U.S. pharma giant copyright scrapped two experimental weight loss products last 12 months—a the moment-day-to-day tablet, lotiglipron, on account of elevated liver enzymes and a 2 times-daily pill, danuglipron, on account of potent Uncomfortable side effects—but CEO Albert Bourla has stated the company is decided to “Perform and acquire” wi